[(1R,1'R,3'R,4R,4'R,5R,5'R,6'R,10'S,12'S,13'S,16'R,18'S,21'R)-1,4',6',12',17',17'-hexamethyl-18'-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3'-yl] acetate; beta-D-Xylopyranoside, (3beta,12beta,16beta,23S,24R,25R)-12-(acetyloxy)-16,23:23,26: 24,25-triepoxy-9,19-cyclolanostan-3-yl
23-Epi-26-deoxyactein is a fully characterized chemical compound used as a reference standard of API Actein. The standard offered is compliant with regulatory guidelines. 23-Epi-26-deoxyactein is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - 501938-01-8
